{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"25"}],"units":"Participants"}],"groups":[{"description":"Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"BG000","title":"Safety run-in Cohort 1"},{"description":"Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"BG001","title":"Safety run-in Cohort 2"},{"description":"Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"BG002","title":"Safety run-in Cohort 3"},{"description":"Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"BG003","title":"Safety run-in Cohort 4"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"20.68","value":"50.5"},{"groupId":"BG001","spread":"19.21","value":"43.6"},{"groupId":"BG002","spread":"14.61","value":"54.7"},{"groupId":"BG003","spread":"19.8","value":"46.0"},{"groupId":"BG004","spread":"18.07","value":"48.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"23"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"25"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Safety Analysis Set"}